cx-4945 has been researched along with Oral-Submucous-Fibrosis* in 1 studies
1 other study(ies) available for cx-4945 and Oral-Submucous-Fibrosis
| Article | Year |
|---|---|
Small Molecule "Silmitasertib" Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis.
Oral submucous fibrosis (OSMF) is considered a premalignant condition characterized by aggressive fibrosis of the submucosal tissues of the oral cavity reflecting its malignant transformation potential. Activation of transforming growth factor beta (TGF- Topics: Drug Repositioning; Humans; Hydrogen Bonding; Molecular Docking Simulation; Naphthyridines; Oral Submucous Fibrosis; Phenazines; Protein Binding; Protein Structure, Secondary; Small Molecule Libraries; Time Factors; Transforming Growth Factor beta1 | 2021 |